Pericardial Involvement in CMML: Terminology and Management
When blast cells infiltrate the pericardium without forming a solid mass in a CMML patient with pericardial effusion, this represents extramedullary disease (EMD) or pericardial involvement by CMML, and should be managed with systemic chemotherapy as the primary approach.
Terminology and Classification
The finding of blast cells in pericardial tissue without a discrete tumor mass represents extramedullary disease (EMD) or pericardial involvement by CMML 1, 2. This differs from a myeloid sarcoma (also called granulocytic sarcoma or chloroma), which presents as a solid tumor mass of myeloid blasts 3.
- Pericardial involvement indicates infiltration of CMML cells into the pericardium, typically manifesting as pericardial effusion containing monocytes and blast cells
- This is a form of non-hepatosplenic EMD, which occurs in 10-15% of CMML patients and carries adverse prognostic implications 2
- The presence of EMD is associated with proliferative CMML phenotypes, higher blast counts, and enrichment of RAS/MAPK pathway mutations 2
Diagnostic Confirmation
The diagnosis requires:
- Tissue confirmation from pericardial biopsy showing blast cells and monocytic infiltration
- Immunophenotyping with CD68, CD163, and lysozyme to confirm monocytic lineage 2
- Cytology of pericardial fluid typically shows predominance of monocytes 4, 5, 6
- Molecular profiling to establish clonality and identify the same mutations present in bone marrow 2
Prognostic Implications
This finding indicates high-risk disease with poor prognosis:
- EMD is associated with shorter overall survival and increased risk of AML transformation 2
- Pericardial involvement can be life-threatening, causing cardiac tamponade requiring urgent intervention 3, 7, 4
- EMD typically occurs during uncontrolled leukocytosis and reflects aggressive disease biology 4
Management Strategy
Immediate Management
- Address cardiac tamponade if present: Pericardiocentesis or pericardial window for symptomatic relief 3, 7
- Initiate systemic therapy promptly - local measures alone are insufficient
Systemic Treatment Approach
Primary systemic therapy is essential because pericardial involvement represents disseminated disease 1, 2:
For CMML-2 with high blast count (≥10% bone marrow blasts):
- Hypomethylating agents (HMAs) such as azacitidine are the backbone of therapy 1, 2
- Intensive chemotherapy may be considered for patients with CMML-2 and high blast burden, particularly if transformation to AML is occurring 1
- Etoposide has shown efficacy in historical case reports of CMML with pericardial effusion, with rapid response 4, 5, 6
For proliferative CMML with lower blast count:
- Cytoreductive therapy with hydroxyurea to control leukocytosis 1
- This is particularly relevant since pericardial effusions in CMML typically develop during uncontrolled leukocytosis 4
Definitive Treatment
Allogeneic hematopoietic cell transplantation (allo-HCT) should be strongly considered 8, 1, 2:
- EMD identifies patients with adverse disease biology who are at high risk for progression
- The 2024 EBMT guidelines recommend that once a patient is identified as a transplant candidate, upfront transplantation should be pursued to maximize chances of reaching allo-HCT 8
- Allo-HCT remains the only potentially curative option for CMML 8, 1
- Early consideration of transplant is particularly important in EMD cases given the poor prognosis 2
Treatment Sequence
- Stabilize hemodynamics with pericardial drainage if tamponade present
- Initiate systemic therapy immediately: HMA (azacitidine) for CMML-2 with high blasts, or cytoreductive therapy for proliferative disease
- Evaluate for allo-HCT eligibility urgently, as EMD indicates high-risk disease
- Proceed to transplant in eligible patients without delay once disease control is achieved
Critical Pitfalls to Avoid
- Do not rely on local therapy alone (pericardiocentesis, pericardial window, or radiation) - systemic disease requires systemic treatment 2
- Do not delay transplant evaluation - EMD indicates aggressive biology requiring definitive therapy 8, 2
- Do not mistake this for infection or inflammatory pericarditis - tissue diagnosis with immunophenotyping is essential 2
- Monitor closely after initial response - pericardial effusions may persist despite peripheral blood response, requiring continued systemic therapy 5